With 0.83 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.24 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $7.1199 whereas the lowest price it dropped to was $5.98. The 52-week range on CV shows that it touched its highest point at $15.37 and its lowest point at $3.43 during that stretch. It currently has a 1-year price target of $10.50.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CV was up-trending over the past week, with a rise of 2.13%, but this was down by -48.08% over a month. Three-month performance surged to 35.14% while six-month performance rose 36.92%.
Float and Shares Shorts:
At present, 46.80 million CV shares are outstanding with a float of 28.63 million shares on hand for trading. On 2025-12-31, short shares totaled 0.22 million, which was 47.0 higher than short shares on 1764288000. In addition to Mr. Kang Huai Wang as the firm’s Co-Founder, President, CEO & Director, Mr. Douglas Atkinson serves as its Senior Vice President of Global Sales.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, CV reported revenue of $3538000.0 and operating income of -$8019000.0. The EBITDA in the recently reported quarter was -$7876000.0 and diluted EPS was -$0.17.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With CV analysts setting a high price target of 14.0 and a low target of 7.0, the average target price over the next 12 months is 10.5. Based on these targets, CV could surge 124.72% to reach the target high and rise by 12.36% to reach the target low. Reaching the average price target will result in a growth of 68.54% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Based on analyst estimates, the high estimate for the next quarter is -$0.12 and the low estimate is -$0.12. The average estimate for the next quarter is thus -$0.12.
